Oculis rings the Nasdaq Iceland opening bell
Oculis became dual-listed on the Nasdaq Iceland Main Market, complementing its existing listing on the Nasdaq Global Market in the U.S. (Nasdaq: OCS).
Oculis rings the Nasdaq Iceland opening bell! 🇮🇸 🔔
Oculis became dual-listed on the Nasdaq Iceland Main Market, complementing its existing listing on the Nasdaq Global Market in the U.S. (Nasdaq: OCS).
Preceding the Iceland listing, Oculis successfully closed an oversubscribed equity financing round of $59 million. This funding round included new Icelandic institutional investors as well as participation from existing investors, thereby extending the cash runway until the second half of 2026 and remain on track for significant catalysts in the innovative pipeline.
Later this quarter, we anticipate the readout from Phase 2b RELIEF trial of OCS-02 in Dry Eyes Disease (DED). 👁
AviLabs has secured €8M in Series A funding to tackle airline passenger disruptions.
DTE has successfully managed to close a $16M Series A round in 2023
The history of Icelandic VC funds and the Icelandic start-up ecosystem.
Exceptional growth for start-up company hopp
